13F reference period
Q2 2026
Security Snapshot
LB PHARMACEUTICALS INC - Common Stock, $0.0001 par value (LBRX) Institutional Ownership
CUSIP: 50180M108
13F Institutional Holders and Ownership History from Q3 2025 to Q3 2026
Institutions Reporting
114
Shares (Excl. Options)
29.76M
Full value: 29,757,846 · shares · 30 Jun 2026Price
$32.46
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value
- Symbol
- LBRX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 29,757,846
- Total 13F value
- $965,858,226
- Portfolio coverage rank
- 0%
- Share change
- +1,521,781
- Value change
- +$49,418,568
- Number of holders
- 114
- Shares outstanding
- 32,599,767
- SEC-reported price per share
- $38.38
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- LBRX - LB PHARMACEUTICALS INC - Common Stock, $0.0001 par value is tracked under CUSIP 50180M108.
- 114 institutions reported positions in Q2 2026.
- 10 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 77 to 114 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$692.42M
Full value: $692,418,818 · USD · 31 Mar 2026.$965.86M
Full value: $965,858,226 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 114 institutions filings for Q2 2026.
Security key
50180M108
13F reference period
Q2 2026
13F holders
114
13D/G owners
10
CIK / CUSIP context first
Open Q2 2026 holders
LBRX full holder history
LB PHARMACEUTICALS INC SEC filings
LB PHARMACEUTICALS INC company facts
LB PHARMACEUTICALS INC insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 50180M108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
10
Security
LBRX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Deep Track Capital, LP | 15% | 3,352,804 | Deep Track Capital, LP | 12 Sep 2025 | ||||
| RA CAPITAL MANAGEMENT, L.P. | 8.7% | +15% | $42,029,734 | +$10,154,484 | 2,208,604 | +32% | RA Capital Management, L.P. | 31 Dec 2025 |
| Commodore Capital LP | 6.8% | +22% | $48,007,461 | +$18,190,961 | 1,972,369 | +61% | Commodore Capital LP | 31 Mar 2026 |
| BlackRock, Inc. | 6.3% | +24% | $58,307,881 | +$16,836,894 | 1,796,543 | +41% | BlackRock, Inc. | 30 Jun 2026 |
| TCG Crossover GP II, LLC | 5% | -23% | $48,354,627 | -$13,102,700 | 1,447,310 | -21% | TCG Crossover GP II, LLC | 30 Jun 2026 |
| Caligan Partners LP | 5% | $35,002,624 | 1,438,070 | Caligan Partners LP | 31 Mar 2026 | |||
| Pontifax Management 4 G.P. (2015) Ltd. | 6.3% | 1,411,681 | Pontifax Management 4 G.P. (2015) Ltd. | 12 Sep 2025 | ||||
| JPMORGAN CHASE & CO | 4.3% | -18% | $53,798,457 | -$3,665,252 | 1,401,790 | -6.4% | JPMORGAN CHASE & CO. | 30 Sep 2026 |
| Trails Edge Capital Partners, LP | 5% | $20,964,420 | 1,268,265 | Trails Edge Capital Partners, LP | 24 Dec 2025 | |||
| BlackRock Portfolio Management LLC | 3.8% | -35% | $21,391,244 | -$308,063 | 961,158 | -1.4% | BlackRock Portfolio Management LLC | 31 Dec 2025 |
As of 30 Jun 2026,
114
institutional investors reported holding
shares of
LB PHARMACEUTICALS INC - Common Stock, $0.0001 par value (LBRX).
This represents
91%
of the company’s total
outstanding shares.
29.76M
Full value: 29,757,846 · shares · 30 Jun 202632.6M
Full value: 32,599,767 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
81%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 10% | 3,352,804 | 0% | 1.6% | $108,815,254 |
| BlackRock, Inc. | 8.4% | 2,734,305 | +11% | 0% | $88,741,868 |
| RA CAPITAL MANAGEMENT, L.P. | 6.8% | 2,208,604 | 0% | 0.62% | $71,680,243 |
| Trails Edge Capital Partners, LP | 4.7% | 1,523,022 | +15% | 7.8% | $49,429,679 |
| Commodore Capital LP | 4.6% | 1,500,000 | 0% | 2.9% | $48,682,500 |
| JPMORGAN CHASE & CO | 4.6% | 1,497,293 | +4.9% | 0% | $48,871,644 |
| TCG Crossover Management, LLC | 4.4% | 1,447,310 | -21% | 1.1% | $46,972,446 |
| Caligan Partners LP | 4.4% | 1,438,070 | 0% | 2.3% | $46,672,562 |
| Spruce Street Capital LP | 4.2% | 1,376,159 | 0% | 8.8% | $44,663,240 |
| Nantahala Capital Management, LLC | 3.2% | 1,052,894 | 0% | 2.1% | $34,171,675 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3% | 971,165 | +8.6% | 0% | $31,519,160 |
| Balyasny Asset Management L.P. | 2.8% | 921,471 | -0.24% | 0.05% | $29,906,341 |
| Alyeska Investment Group, L.P. | 2.7% | 863,947 | 0% | 0.07% | $28,039,400 |
| Vivo Capital, LLC | 2.5% | 800,000 | 0% | 2.4% | $25,964,000 |
| Nan Fung Group Holdings Ltd | 1.9% | 630,657 | 0% | 16% | $20,467,973 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.9% | 612,793 | +18% | 0% | $19,893,259 |
| STATE STREET CORP | 1.8% | 602,028 | +19% | 0% | $19,538,819 |
| Logos Global Management LP | 1.8% | 585,000 | -36% | 0.82% | $18,986,175 |
| GOLDMAN SACHS GROUP INC | 1.8% | 576,456 | +58% | 0% | $18,708,879 |
| JENNISON ASSOCIATES LLC | 1.7% | 540,902 | +0.5% | 0.01% | $17,554,973 |
| GREAT POINT PARTNERS LLC | 0.97% | 317,221 | +5.7% | 2.4% | $10,295,408 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.85% | 275,675 | 0.17% | $8,947,032 | |
| MILLENNIUM MANAGEMENT LLC | 0.8% | 259,219 | +89% | 0.01% | $8,412,953 |
| AMERIPRISE FINANCIAL INC | 0.7% | 227,485 | +110% | 0% | $7,383,026 |
| CITADEL ADVISORS LLC | 0.66% | 215,969 | -48% | 0% | $7,009,274 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
5
Headline period
Q2 2026
Rows shown
1-5 of 5
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 136,069 | $5,210,098 | +$3,021,668 | $38.38 | 16 |
| 2026 Q2 | 29,757,846 | $965,858,226 | +$49,418,568 | $32.46 | 114 |
| 2026 Q1 | 28,209,904 | $692,418,818 | +$82,664,759 | $24.66 | 77 |
| 2025 Q4 | 24,789,567 | $551,818,582 | +$64,572,138 | $22.26 | 67 |
| 2025 Q3 | 19,945,854 | $314,944,399 | +$314,944,399 | $15.79 | 53 |